Thursday 16 October, 2025
Introduction: The adverse effects of AI except on the musculoskeletal system are less than tamoxifen in breast cancer patients, but…
Read morePoster: Drug/Disease Modelling - Oncology
Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy
Thursday 16 October, 2025
Introduction: Drug development for multiple myeloma (MM) is complex for multiple reasons: 1) long durations to demonstrate clinical benefit (overall…
Read moreLutathera dose determination and justification in adolescents via population PK and dosimetry modeling and simulation
Thursday 16 October, 2025
Introduction: [177Lu]Lu-DOTA-TATE (Lutathera®) is an approved drug used for the treatment of somatostatin receptor-positive (SSTR-positive) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)…
Read moreSimulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer
Thursday 16 October, 2025
Introduction: In oncology, the sum of longest diameters (SLD) is commonly used to follow the dynamics of patient tumor size…
Read morePharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia
Thursday 16 October, 2025
Introduction: Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPCs) in bone marrow is a major cause of anemia and…
Read moreA joint K-PD model with the tumor size changes and CA-125 kinetics in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study.
Thursday 16 October, 2025
Objectives: In patients with recurrent advanced ovarian cancer (AOC), the development of combined immunotherapy + anti-angiogenic + PARP inhibitor agents…
Read morePrognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study
Thursday 16 October, 2025
Objectives: In patients with recurrent High Grade Ovarian Cancer (HGOC), the combination of durvalumab (anti-PL1 monoclonal antibody), olaparib (PARP inhibitor)…
Read moreSeparating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data
Thursday 16 October, 2025
Introduction: Tamoxifen (TAM) is a prodrug used in the treatment of oestrogen receptor-positive breast cancer, with Z-endoxifen (Z-EDX) being its…
Read moreQuantifying the impact of CYP2D6 allele activity on Z-endoxifen formation leveraging the multi-study CEPAM database: Towards treatment optimisation of tamoxifen
Thursday 16 October, 2025
Introduction: Tamoxifen (TAM) is a prodrug established in the treatment of oestrogen receptor-positive breast cancer, yet 25% of patients experience…
Read moreUse of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa (Nemvaleukin), an Investigational Cancer Immunotherapy
Thursday 16 October, 2025
Objectives: Nemvaleukin is a novel engineered protein designed to selectively bind the intermediate-affinity interleukin-2 receptor, preferentially expanding antitumor CD8+ T…
Read more